作者
Deepak L Bhatt, Michael Szarek, P Gabriel Steg, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra, Lars H Lund, Michel Komajda, Jeffrey M Testani, Christopher S Wilcox, Piotr Ponikowski, Renato D Lopes, Subodh Verma, Pablo Lapuerta, Bertram Pitt
发表日期
2021/1/14
期刊
New England journal of medicine
卷号
384
期号
2
页码范围
117-128
出版商
Massachusetts Medical Society
简介
Background
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated heart failure are unknown.
Methods
We performed a multicenter, double-blind trial in which patients with type 2 diabetes mellitus who were recently hospitalized for worsening heart failure were randomly assigned to receive sotagliflozin or placebo. The primary end point was the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure (first and subsequent events). The trial ended early because of loss of funding from the sponsor.
Results
A total of 1222 patients underwent randomization (608 to the sotagliflozin group and 614 to the placebo group) and were followed …
学术搜索中的文章
DL Bhatt, M Szarek, PG Steg, CP Cannon, LA Leiter… - New England journal of medicine, 2021